EDUCATIONAL SECTIONCell production rates in human tissues and tumours and their significance. Part II: clinical data
References (94)
- et al.
Lack of predictive value of potential doubling time and iodeoxyuridine labelling index in radiotherapy of squamous cell carcinoma of the head and neck
Radiotherapy and Oncology
(1998) - et al.
Do cell kinetics have prognostic and/or predictive value in oesophageal cancer treated by surgery?
Eur J Surg Oncol
(1997) - et al.
Immunohistochemical study of epithelial cell proliferation in hyperplastic polyps, adenomas, and adenocarcinomas of the large bowel
Gastroenterology
(1988) - et al.
Factors influencing the estimates of proliferative labelling indices in rectal cancer
Radiother Oncol
(1998) - et al.
The flow cytometric analysis of total p53 protein content and proliferation indices in colorectal cancer, in relation to clinical outcome
Eur J Surg Oncol
(1996) - et al.
Quantitative indices of proliferation using bromodeoxyuridine: A study of sixty invasive breast carcinomas
The Breast
(1993) - et al.
Cell kinetics of human ovarian cancer with in vivo administration of bromodeoxyuridine
Annals Oncol
(1994) - et al.
Proliferation measurements with flow cytometry Tpot in cancer of the uterine cervix: correlation between two laboratories and preliminary clinical results
Int J Radiat Oncol Biol Phys
(1995) - et al.
In situ cell cycle kinetics in bone marrow biopsies following sequential infusions of IUdR/BrdUrd
Leuk Res
(1992) - et al.
S phase fraction of human bladder tumor measured in situ with bromodeoxyuridine labeling
J Urol
(1988)
Immunochemical demonstration of S phase cells by anti-bromodeoxyuridine monoclonal antibody in human prostate adenocarcinoma
J Urol
Role of proliferative activity estimated by BrdUrd labeling index in determining predictive factors of recurrence in superficial intermediately malignant bladder tumors
J Urol
Cell kinetic measurements in prostate cancer
Int J Radiat Biol Phys
Studies with bromodeoxyuridine in head and neck cancer and accelerated radiotherapy
Radiother Oncol
Experience with CHART
Int J Radiat Oncol Biol Phys
In vivo measurement of the potential doubling time by flow cytometry in oropharyngeal cancer treated by conventional radiotherapy
Int J Radiat Oncol Biol Phys
Potential doubling time in head and neck tumors treated by primary radiotherapy: preliminary evidence for a prognostic significance in local control
Int J Radiat Oncol Biol Phys
The predictive value of cell kinetic measurements in a European trial of accelerated fractionation in advanced head and neck tumors: an interim report
Int J Radiat Oncol Biol Phys
Predictive value of potential doubling time for radiotherapy of hand and neck tumour patients: results from the EORTC cooperative trial 22851
Seminars in Radiat Oncol
Potential doubling time and clinical outcome in head and neck squamous cell carcinomas treated with 70 GY in 7 weeks
Int J Radiat Oncol Biol Phys
Accelerated radiation therapy for locally advanced squamous cell carcinomas of the oral cavity and oropharynx selected according to tumor cell kinetics—a phase II multicenter study
Int J Radiat Oncol Biol Phys
Predictive value of potential doubling time in head and neck cancer patients treated by conventional radiotherapy
Int J Radiat Oncol Biol Phys
Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial
Radiother Oncol
The value of pretreatment cell kinetic parameters as predictors for radiotherapy outcome in head and neck cancer: a multicentre analysis
Radiother Oncol
Cell proliferation rates in human tissues and tumours: Part I
Eur J Surg Oncol
Bromodeoxyuridine: a diagnostic tool in biology and medicine, Part I: Historical perspectives, histochemical methods and cell kinetics [Review]
Histochem J
Bromodeoxyuridine: a diagnostic tool in biology and medicine, Part II: Oncology, chemotherapy and carcinogenesis
Histochem J
Tumour growth rates in squamous carcinoma of the head and neck measured by in vivo bromodeoxyuridine
Br J Cancer
A comparison of cellular proliferation markers in squamous cell carcinoma of the head and neck
J Laryngol Otol
Cell kinetics of head and neck squamous cell carcinomas. Prognostic implications
Acta Oncol
Tumour proliferation assessed by combined histological and flow cytometric analysis: implications for therapy in squamous cell carcinoma in the head and neck
Br J Cancer
Combined flow cytometry and immunohistochemistry analyses for the assessment of nasopharyngeal carcinoma cell kineticsin vivo by bromodeoxyuridine infusion
Cytometry
Proliferative characteristics of head and neck tumours. In vivo evaluation by BrdUrd incorporation and flow cytometry Orl
J Oto-Rhino-Laryngol
In vivo labelling with halogenated pyrimidines of squamous cell carcinomas and adjacent non-involved mucosa of head and neck region
Cell Proliferation
Cell kinetics of head and neck cancers
Clin Cancer Res
Cyclin D1 expression in squamous cell carcinomas of the head and neck and in oral mucosa in relation to proliferation and apoptosis
Clinical Cancer Res
Prospective evaluation of cell kinetics in head and neck squamous carcinoma: the relationship to tumour factors and survival
Br J Cancer
Proliferative potential of recurrent intracranial meningiomas as evaluated by labelling indices of BrdUrd and Ki-67, and tumour doubling time
Acta Neurochirurgica
Cell kinetics in human malignancies studied with in vivo administration of bromodeoxyuridine and flow cytometry
Cancer Res
Prognostic value of DNA ploidy and proliferative activity in human malignant gliomas
Med Sci Res
A new method for analyzing the cell kinetics of human brain tumors by double labeling with bromodeoxyuridine in situ and with iododeoxyuridine in vitro
Cancer
S phase fraction, bromodeoxyuridine labelling index, duration of S phase, potential doubling time and DNA index in benign and malignant brain tumours
Radiation Oncol Investigations
Prognostic relevance of cell proliferation markers and DNA ploidy in gliomas
Acta Neurochirurgica
Assessment of human tumour proliferation using bromodeoxyuridine—current status
Acta Oncologica
The in vivo proliferation kinetics of human solid tumors
MChir Thesis, University of Cambridge, UK
In vivo cell kinetic measurements in human oesophageal cancer: what can be learned from multiple biopsies?
Eur J Cancer
In vivo growth kinetic measurements in human oesophageal cancer
PhD Thesis, University of Leiden, Holland
Cited by (113)
Epigenetic therapy: Research progress of decitabine in the treatment of solid tumors
2024, Biochimica et Biophysica Acta - Reviews on CancerRadiotherapy treatment interruptions during the Covid-19 pandemic: The UK experience and implications for radiobiology training
2022, Radiation Physics and ChemistryChaos and multistability behaviors in 4D dissipative cancer growth/decay model with unstable line of equilibria
2022, Chaos, Solitons and FractalsCitation Excerpt :The tumor cell production rate (α) may be hypothesized to influence the tumor response to chemotherapy or radiotherapy. In the absence of cell loss and other factors influencing biological aggressiveness (such as invasiveness, metastatic potential), rapidly proliferating tumors might be expected to repopulate more rapidly during treatment, and thus be relatively resistant to treatment and may mandate more frequent courses of therapy to destroy the proliferating cells [53]. Therefore, the bifurcation analysis is done and bifurcation diagrams are obtained when tumor cell production rate (α) ranges between 0 ≤ α ≤ 1.
Exact site frequency spectra of neutrally evolving tumors: A transition between power laws reveals a signature of cell viability
2021, Theoretical Population BiologyCyclin B1/CDK1-regulated mitochondrial bioenergetics in cell cycle progression and tumor resistance
2019, Cancer LettersCitation Excerpt :Cyclin B1, as the most important catalytic partner of CDK1, has been unearthed to be abnormally activated and aberrantly expressed in a number of human cancers including esophageal squamous cell carcinoma, laryngeal squamous cell carcinoma, and colorectal carcinomas [105–107]. Besides, cyclin B1 is linked with anti-apoptosis and tumor resistance in head and neck cancer [108,109], one of the most aggressive cancers [110], triggers tumor proliferation and links with poor prognosis in esophageal squamous cell carcinoma [111], non-small cell lung cancer [112], and colorectal carcinoma [113]. Consistently, deficiency of cyclin B1 causes inhibition of cell proliferation and activation of apoptosis [114] and activated cyclin B1 leads to a pro-survival machinery mediated by the NF-κB signaling network [115].